Literature DB >> 14583456

Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy.

Natalia L Komarova1, Dominik Wodarz.   

Abstract

Genetic instability is a central characteristic of cancers. However, the selective forces responsible for the emergence of genetic instability are not clear. We use mathematical models to determine the conditions under which selection favors instability, and when stable cells are advantageous. We take into account the processes of DNA damage, repair, cell cycle arrest, mutation, and death. We find that the rate of DNA damage can play a major role in this context. In particular, an increase in the rate of DNA damage can reverse the relative fitness of stable and unstable cells. In terms of cancer progression, we find the following results. If cells have intact apoptotic responses, stable cells prevail if the DNA hit rate is low. A high DNA hit rate can result in the selection of genetically unstable cells. This has implications for the induction of tumors by carcinogens. On the other hand, if cells are characterized by impaired apoptosis, we observe the opposite. Genetic instability is selected for if the DNA hit rate is low. A high DNA hit rate can select against instability and result in the persistence of stable cells. We propose that chemotherapy can be used to reverse the relative fitness of stable and unstable cells, such that unstable cells are the inferior competitors. This could result in the competitive exclusion of progressing cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Negative clonal selection in tumor evolution.

Authors:  Robert A Beckman; Lawrence A Loeb
Journal:  Genetics       Date:  2005-09-02       Impact factor: 4.562

Review 2.  Modeling head and neck cancer stem cell-mediated tumorigenesis.

Authors:  Alexander T Pearson; Trachette L Jackson; Jacques E Nör
Journal:  Cell Mol Life Sci       Date:  2016-05-05       Impact factor: 9.261

Review 3.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

Review 4.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

5.  Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.

Authors:  Andrii I Rozhok; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

Review 6.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.

Authors:  M Gerlinger; C Swanton
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

7.  The optimal rate of chromosome loss for the inactivation of tumor suppressor genes in cancer.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-22       Impact factor: 11.205

8.  Selective pressures for and against genetic instability in cancer: a time-dependent problem.

Authors:  Natalia L Komarova; Alexander V Sadovsky; Frederic Y M Wan
Journal:  J R Soc Interface       Date:  2008-01-06       Impact factor: 4.118

9.  Noise-induced bistability in the fate of cancer phenotypic quasispecies: a bit-strings approach.

Authors:  Josep Sardanyés; Tomás Alarcón
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

10.  Mutator mutations enhance tumorigenic efficiency across fitness landscapes.

Authors:  Robert A Beckman
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.